Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the FDA has placed a clinical hold on its Phase 2 trial for KVD824, an oral candidate for hereditary angioedema (HAE). The FDA requested further information and refinements to the study protocol without demanding new studies. CEO Andrew Crockett expressed intent to comply with FDA requests, noting that this hold does not affect the development of KVD900, which is preparing for a Phase 3 trial. Historical data show safe dosing of KVD824 in prior studies, with no serious adverse events reported.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Nancy Stuart to its Board of Directors, effective March 18, 2021. Stuart, currently COO at Concert Pharmaceuticals, brings over 25 years of experience in the biopharmaceutical industry. CEO Andrew Crockett highlighted her strategic and operational expertise as valuable for the company's transition to a commercial-stage organization focusing on oral treatments for hereditary angioedema (HAE). KalVista is advancing clinical-stage assets, including KVD900, an oral therapy for acute HAE attacks, which recently showed positive Phase 2 trial results.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) provided a Q3 fiscal update ending January 31, 2021, highlighting significant progress in treating hereditary angioedema (HAE) with KVD900 and KVD824. KVD900 showed strong Phase 2 results, significantly outperforming placebo on multiple endpoints. The company closed a public offering, raising approximately $222.5 million. However, revenue fell to $0 from $1.6 million due to the expiration of the Merck Option Agreement. Net loss increased to $10.1 million, while cash reserves decreased to $50.3 million, attributed to R&D spending.
KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. A live webcast will be available on the company's website, along with an audio archive for 30 days post-event.
KalVista focuses on developing small molecule protease inhibitors, including KVD900 for acute hereditary angioedema (HAE) attacks and KVD824 for prophylactic HAE treatment, with significant clinical trial advancements in early 2021.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has successfully closed its upsized public offering, selling 6,181,250 shares at $36.00 each, raising approximately $222.5 million in gross proceeds. This includes the underwriters' option for an additional 806,250 shares. Jefferies LLC, Stifel, Nicolaus & Company, and Cantor Fitzgerald acted as joint book-running managers. The offering is registered with the SEC and follows prior effective registration statements. KalVista specializes in developing small molecule protease inhibitors for critical diseases, including hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has priced its upsized public offering of 5,375,000 shares of common stock at $36.00 per share, projecting gross proceeds of $193.5 million. The offering will close around February 16, 2021, pending customary conditions. An additional 806,250 shares may be purchased by underwriters. Funds will support the Phase 3 trial of KVD900, Phase 2 trial of KVD824, and development of oral Factor XIIa programs. Jefferies, Stifel, and Cantor Fitzgerald are managing the offering.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) plans to offer 4,500,000 shares of common stock in an underwritten public offering, with an additional 675,000 shares available for underwriters. The capital raised aims to finance a Phase 3 trial of KVD900 and a Phase 2 trial of KVD824, along with the development of its oral Factor XIIa programs. The offering is contingent upon market conditions and follows a shelf registration statement effective since December 2018. Jefferies, Stifel, and Cantor Fitzgerald will manage the offering.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive topline data from a Phase 2 trial of KVD900, an oral treatment for hereditary angioedema (HAE) attacks. The trial showed statistically significant efficacy, with KVD900 resulting in a 15% rate of rescue medication use compared to 30% for placebo at 12 hours (p=0.001). Symptom relief onset was significantly faster with KVD900, taking 1.6 hours versus 9 hours for placebo (p<0.0001). No serious adverse events were reported, showcasing KVD900's favorable safety profile. A presentation of the trial data will be available on their website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported no revenue for the second fiscal quarter ended October 31, 2020, down from $3.9 million the previous year, due to the expiration of the Merck Option Agreement. A net loss of $10.4 million, or $(0.58) per share, was observed, compared to a loss of $5.9 million, or $(0.33) per share, in the same quarter last year. The company completed patient treatment in a Phase 2 trial for KVD900, with data expected in Q1 2021. Additionally, an IND submission for KVD824 is anticipated in Q1 2021, aiming for a twice-daily oral treatment for hereditary angioedema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two investor conferences: Stifel 2020 Virtual Healthcare Conference on November 16 at 10:40 a.m. EST and Jefferies Virtual London Healthcare Conference on November 19 at 3:50 p.m. GMT. A live webcast of the presentations will be available on the company's website, with an audio archive accessible for 30 days afterward. The company focuses on small molecule protease inhibitors targeting diseases like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for treatments such as KVD900 and KVD824.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
